The UC Davis Cancer Center, the only NCI-designated cancer center in the Central Valley of California, is the advanced cancer care provider for a population of five million, the only significance point of access to early phase cancer clinical trials in its Northern California region, and together with its collaborator, the Lawrence Livermore National Laboratory [LLNL], the region's principal cancer research organization. Since its founding thirteen years ago, the UC Davis Cancer Center has provided increasingly progressive leadership to, organization of, and support for cancer investigation. In the first sections, we recapitulate briefly the milestones leading up to NCI designation (July 1, 2002). In subsequent sections, we focus on decisions, achievements, and directions characterizing the center's first two years of its Cancer Center Support Grant [CCSG]. In concluding sections, we focus on program and organizational accomplishments, future direction, and geography.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA093373-04S1
Application #
7121743
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
2002-07-01
Project End
2006-06-30
Budget Start
2005-07-01
Budget End
2006-06-30
Support Year
4
Fiscal Year
2005
Total Cost
$244,598
Indirect Cost
Name
University of California Davis
Department
Urology
Type
Schools of Medicine
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Matsumoto, Collin; Jiang, Yan; Emathinger, Jacqueline et al. (2018) Short Telomeres Induce p53 and Autophagy and Modulate Age-Associated Changes in Cardiac Progenitor Cell Fate. Stem Cells 36:868-880
Turner, David C; Kondic, Anna G; Anderson, Keaven M et al. (2018) Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance. Clin Cancer Res 24:5841-5849
Gandara, David R; Riess, Jonathan W; Lara Jr, Primo N (2018) In Search of an Oncogene Driver for Squamous Lung Cancer. JAMA Oncol 4:1197-1198
Long, Qilai; Lin, Tzu-Yin; Huang, Yee et al. (2018) Image-guided photo-therapeutic nanoporphyrin synergized HSP90 inhibitor in patient-derived xenograft bladder cancer model. Nanomedicine 14:789-799
Withers, Sita S; Moore, Peter F; Chang, Hong et al. (2018) Multi-color flow cytometry for evaluating age-related changes in memory lymphocyte subsets in dogs. Dev Comp Immunol 87:64-74
Riess, Jonathan W; Gandara, David R; Frampton, Garrett M et al. (2018) Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC. J Thorac Oncol 13:1560-1568
Rowson-Hodel, A R; Wald, J H; Hatakeyama, J et al. (2018) Membrane Mucin Muc4 promotes blood cell association with tumor cells and mediates efficient metastasis in a mouse model of breast cancer. Oncogene 37:197-207
Zhang, Jin; Xu, Enshun; Ren, Cong et al. (2018) Genetic Ablation of Rbm38 Promotes Lymphomagenesis in the Context of Mutant p53 by Downregulating PTEN. Cancer Res 78:1511-1521
York, D; Sproul, C D; Chikere, N et al. (2018) Expression and targeting of transcription factor ATF5 in dog gliomas. Vet Comp Oncol 16:102-107
Wang, Minan; Yao, Li-Chin; Cheng, Mingshan et al. (2018) Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy. FASEB J 32:1537-1549

Showing the most recent 10 out of 836 publications